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Abstract 
Many targeted treatment studies have been carried out in individuals with Fragile X 
Syndrome (FXS) guided by animal studies from the Fragile X Mental Retardation 1 
(FMR1) knock out (KO) mice and the fragile X Drosophila studies. Here we review 
the many medications that have been studied in patients with FXS and some of these 
medications are available for clinical use by wise clinicians. Other medications are not 
currently available by prescription because they are not approved by the FDA. No 
medication has received specific approval for treatment of FXS, although some have 
shown benefit from clinical studies. There is much to be done in the treatment of those 
with FXS and this report describes those pharmacological treatments that target the 
neurobiological mechanisms that are dysregulated by the lack of the FMR1 Protein 
(FMRP) in those with FXS. 
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INTRODUCTION 
  Fragile X syndrome (FXS) is the most common 
single gene disorder which causes intellectual disability 
and autism spectrum disorder (ASD). The estimated 
prevalence in the general population is 1: 3,600 to 4,000 
in males and 1:4,000 to 6,000 in females. Expansion of 
the cytosine-guanine-guanine triplet with more than 200 
repeats on the fragile X mental retardation 1 (FMR1) 
gene, called “full mutation” silences transcription 
leading to the inability to produce the FMR1 protein 
(FMRP).  
 FMRP is expressed in various tissues and most 
prominently in the CNS and it is a key promoter of 
synaptic plasticity. FMRP regulates mRNA translation 
of hundreds of genes usually with inhibition. Therefore, 
deficient FMRP expression usually leads to enhanced 
protein production which includes upregulation of the 
excitatory metabotropic glutamate receptor 5 (mGluR5) 
pathway causing long term depression (LTD) of synaptic 
connections, α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) receptor internalization, 
increasing eukaryotic translation initiation factor 4E 
(eIF4E) phosphorylation, enhanced activity of 
extracellular signal-regulated kinase (ERK), and 
elevated matrix metalloproteinase-9 (MMP-9) levels.2 In 
addition, the lack of FMRP leads to deficits in inhibitory 
gamma-aminobutyric acid (GABA) signaling as well as 
dopamine and cholinergic dysregulation.1,2 The 
endocannabinoid system, which promotes synaptic 
plasticity, is also dysregulated in FMRP deficient 
conditions as in FXS.2  
 Imbalance of these mechanisms causes increasing 
neuronal hyperexcitability, dysregulation of dendritic 
spine maturation, and disrupted synaptic connections 
leading to intellectual disability and the clinical 
phenotypes of FXS (i.e., over reactivity to stimuli, 
decrease ability in habituation, seizure, hyperactivity, 
anxiety, and cognitive deficit).2 Many research studies 
have been proposed to modify these dysfunctional 
pathways with the aim to find pharmacological 
treatments targeting the aberrant mechanisms in FXS. 
This review describes recent pharmacological studies of 
targeted treatments focused on reversing the 
neurobiological abnormalities of FXS.  
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Metformin 
 Metformin is an antihyperglycemic agent which is 
approved by the Food and Drug Administration (FDA) 
for the treatment of non-insulin dependent diabetes 
mellitus. It has also been the treatment of choice in 
children and adults with obesity and insulin resistance. 
Metformin distributes across the blood-brain barrier and 
the main mechanism of action of metformin in FXS is 
the normalization of the mammalian target of rapamycin 
(mTOR) and mitogen-activated protein kinase/ 
extracellular signal-regulated kinase (MAPK/ERK) 
pathways. Both pathways regulate cellular function 
particularly in the central nervous system (CNS) and 
both are abnormally hyperactivated by the FMRP 
deficient condition. Metformin lowers the level of blood 
glucose by enhancing peripheral glucose uptake and 
glycolysis while inhibiting hepatic gluconeogenesis and 
gastrointestinal glucose absorption.3 The reduction of 
blood glucose causes a decrease of insulin signaling and 
consequently inhibits the mechanistic target of 
rapamycin complex 1 (mTORC1) and MAPK/ERK 
pathways. Moreover, metformin also inhibits the 
mTORC1 and ERK pathways via activation of AMP-
activated protein kinase complex (AMPK)3. MMP-9 
which is upregulated in conditions of FMRP deficiency 
causes a negative impact on synaptic formation in FXS.4 
Metformin also normalizes messenger RNA (mRNA) 
encoding of MMP-9 via reduction of eIF4E 
phosphorylation and mRNA translation. Furthermore, 
metformin indirectly acts on insulin, the risk of 
experiencing hypoglycemia is low in individuals with 
normal renal function and without taking other 
hypoglycemic agents.5,6   
 The efficacy of metformin was proved in Fmr1-
knocked out (KO) animal models by showing 
improvement in abnormal behaviors.7,8 Problematic 
behaviors like hyperphagia and stereotypy have also 
shown improvements in patients with FXS treated 
clinically with metformin9,10. A randomized-controlled 
trial of metformin showed benefits in weight control in 
children and adolescents with ASD experiencing 
atypical antipsychotic-induced weight gain above 
normal body mass index11,12. However, the effects of 
metformin on cognition in children with ASD needs 
more study13. 
 Medical treatment with metformin in seven 
individuals age 4.5-60 years old with FXS produced 
behavioral improvements following the intake of 
metformin clinically for 6-12 months.9 These 
improvements included decreasing in irritability, 
hyperactivity, and social avoidance as well as 
improvement in social responsiveness which were 
measured by using Aberrant Behavior Checklist (ABC). 
While individuals with FXS tend to have cognitive 
decline overtime especially in the verbal communication 
domain14, improvements in language especially 
conversational skills is a welcome change.9 Two 
additional males with FXS (age 25 and 30 years old) 
treated clinically for over one year showed improvement 
in Stanford-Binet Intelligence Scale-5 which included 
visuospatial processing, working memory, numeracy 
skill, and quantitative reasoning after taking 1000 mg of 
metformin once or twice a day.15 Their parents also 
anecdotally reported improvements in language, social 
communication, responsiveness as well as decreasing 
irritability and anxiety.   
 Metformin stimulates neurogenesis in animal 
models.3 Normalizing the excess protein production in 
the CNS in FXS with metformin leads one to predict that 
young children may demonstrate the greatest benefits 
from metformin treatment. A case series report of 9 
children between 2-7 years old has recently illustrated 
benefits of metformin in both developmental and 
behavioral domains.10 Metformin was started at 25-50 
mg at dinner and then titrated up gradually with age. The 
youngest children were 2 years old and the lowest stable 
dose of metformin was 200 mg twice daily (31.01 
mg/kg/day). Aberrant Behavior Checklist-Community 
(ABC-C) scores were improved especially in lethargy 
and stereotypy. Their Mullen Scales of Early Learning 
(MSEL) score were increased in all domains. Some 
parents noted that their child’s communication, problem-
solving abilities, and daily living skills were better in 
addition to decreased tantrums and aggressive behaviors. 
The only common side effect was loose stools which was 
self-limited. However, one child developed seizures 
during the metformin treatment, whereas another child 
demonstrated improvement in seizures that were already 
present before metformin treatment was started. 
 Besides cognitive and behavioral aspects which have 
been considerably improved in some cases, metformin 
was also reported to prevent the development of 
macroorchidism at puberty in an adolescent male with 
FXS who started taking metformin at age 12 before 
puberty16. Metformin might alleviate over production of 
proteins promoting testicular growth. Moreover, 
metformin is specifically considered beneficial in FXS 
with the Prader-Willi-Phenotype, a subgroup of 
individuals with FXS who have severe obesity together 
with hyperphagia and a lack of satiation after 
meals.2,9,15,16     
 Currently, a multi-site randomized controlled trial is 
being conducted which aims to assess efficacy of 
metformin in improving language, cognition and 
behavior in patients between 6 to 25 years old with FXS 
(NCT03479476). Two additional studies also seek to 
assess the safety and tolerability of metformin and its 
effect in behavior (NCT03722290, NCT04141163) (see 
table 1). 
 
Minocycline 
 Minocycline is a semi-synthetic tetracycline 
derivative commonly used to treat acne. It has been of 
interest in the FXS treatment field since animal studies 
showed it to have an inhibitory effect on the activity of 
MMP-917. FMRP deficiency leads to elevated MMP-9 
activity which has a negative impact in synaptic 
physiology and plasticity.4 Treatment of Fmr1-KO mice 
with minocycline normalized MMP-9 levels in brain 
tissues and led to improvement in multiple phenotypes of 
FXS, especially in behavior and cognition domains.17,18 
In an experimental study of chronic minocycline 
treatment in Fmr1-KO mice, Yau et al. showed an 
improvement in hippocampal synaptic structure and N-
methyl-D-aspartate (NMDA) receptor function. These 
findings may explain part of the beneficial cognitive 
effects of minocycline in FXS.19 Toledo et al (2019). 
studied the effect of minocycline treatment in Fmr1-KO 
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mice on ultrasonic vocalization deficits during mating, 
which is an indicator of abnormal social communication. 
They found that minocycline reversed ultrasonic 
vocalization deficits through attenuation of MMP-9 
levels, even when treated past the early developmental 
period.20 Minocycline has also been shown to be 
beneficial in studies involving patients with FXS. Leigh 
and colleagues (2013) published a randomized double-
blind, placebo-controlled crossover trial of minocycline 
in children and adolescents with FXS. Study participants 
were given minocycline for 3 months and placebo for 3 
months. Forty eight of their subjects completed the full 
trial. They found improvements in the Clinical Global 
Impression-Improvement (CGI-I) scale and anxiety and 
mood-related behaviors in the Visual Analog Scale.21 
 Although minocycline is available clinically, its use 
in patients with FXS requires safety monitoring. In a 
survey of clinical response to minocycline in 50 patients 
with FXS performed by Utari et al. (2010), the most 
common side effect reported was gastrointestinal issues 
such as loss of appetite, gastrointestinal discomfort and 
diarrhea. Less frequent side effects reported were 
worsening hyperactivity and moodiness, and one patient 
had darkening of nails.22 Furthermore, an open-label 
study by Paribello et al. involving 19 patients with FXS 
documented dizziness, diarrhea and seroconversion to a 
positive antinuclear antibody (ANA).23 Therefore, 
minocycline is well tolerated but requires clinical 
monitoring and testing for ANA and liver function.24 
 
Sertraline 
 Sertraline is a selective serotonin reuptake inhibitor 
(SSRI) approved for the treatment of anxiety and mood 
disorders in children age 6-17 years old. Compared to 
other SSRIs, sertraline has less activation side effects 
and drug-drug interactions and has been prescribed for 
treatment of anxiety, irritability, and social deficit in 
FXS.25 
 Serotonin in the cortex usually peaks during the first 
five years of life when synaptogenesis is also highest26. 
However, this serotonin trajectory and brain morphology 
in children with ASD was found to be dysregulated.1,26,27 
Serotonin dysregulation is also an abnormal 
neurochemical pathway in FXS.1 Serotonin and the 
brain-derived neurotrophic factor (BDNF) interact 
reciprocally to regulate neuroplasticity26.Treatment with 
an SSRI not only normalizes serotonin levels, but also 
stimulates BDNF which is also dysregulated in FXS.1 In 
the Fmr1-KO mouse model, serotonin also restored 
glutamate A1-dependent long-term potentiation (LTP)28 
and attenuated mGluR5-mediated synaptic LTD.29 
Moreover, dopamine is found impaired in Fmr1-KO 
mice.30 Sertraline is an SSRI which inhibits dopamine 
reuptake1, therefore, leading to an increased dopamine 
concentration at the nucleus accumbent and the striatum 
in rats.31 Normalization of dopamine may help maintain 
normal LTP and dendritic morphology in FXS.1 These 
mechanisms ultimately stabilize neural functions and 
synapse formation. Importantly, treatment with an SSRI 
in young children with FXS could maximize benefits 
since this is the golden period of neuroplasticity.25 
 Benefits of sertraline have been confirmed in 
individuals with FXS. A retrospective chart review 
compared 11 children with FXS who took sertraline with 
34 children with FXS who did not take sertraline25. They 
were between 12-50 months old and the earliest age when 
sertraline was prescribed was 18 months old. The 
indication for sertraline prescription was to treat anxiety 
and social deficits and the average dose was 5.8±2.5 
mg/day. Children who took sertraline had higher 
language scores measured by using the Mullen Scales for 
Early Learning (MSEL) compared to the control group at 
follow-up. Decreased anxiety, irritability, and social 
deficits were also observed. 
 A randomized-controlled trial was conducted in 52 
young children with FXS who took low dose of sertraline 
(2.5 mg/day for children age 2-3 years old and 5 mg/day 
for children age 4-6 years old) for 6 months. The results 
showed significant improvements in visual reception, 
fine motor skills, and MSEL summary age-equivalent 
scores in addition to a measure of social perception.32 In 
children with concomitant FXS and ASD, their 
expressive language development on the MSEL was 
significantly improved on post hoc analysis. Some minor 
side effects commonly seen were upper respiratory tract 
infections and gastrointestinal issues, but these did not 
differ from the placebo group. Although the study was 
completed, parents preferred to continue sertraline 
because of desired developmental outcomes. Long-term 
monitoring of adverse events is necessary and measuring 
efficacy of combined sertraline with language 
intervention should be studied. 
 
Cannabidiol 
 The term ‘cannabinoid’ is used to refer to metabolites 
derived from Cannabis sativa and synthetic compounds 
that act on cannabinoid receptors. Cannabidiol (CBD) is 
a phytocannabinoid that has been studied due to its 
pharmacological potential. In contrast to delta-9-
tetrahydrocannabinol (THC), CBD is not associated with 
psychomimetic properties.33 CBD has several 
mechanisms of action and therefore multiple potential 
therapeutic effects. Several studies have found possible 
beneficial pharmacological effects of CBD in different 
disorders such as epilepsy,34,35 anxiety,36–38 
neurodegenerative diseases such as Alzheimer’s 
disease,39,40 and autoimmune diseases such as rheumatoid 
arthritis,41 among others. 
 In the mouse model of FXS, it has been shown that 
the endocannabinoid system is linked to the biological 
actions of FMRP and is therefore dysregulated when 
there is absence or deficiency of this protein.42,43 
Preclinical models of FXS have shown loss of 
endocannabinoid signaling and many of the 
abnormalities described in FXS such as social and 
cognitive impairment, seem to be associated to the 
dysregulation of the endocannabinoid pathways in the 
CNS44. The loss of endocannabinoid signaling in the FXS 
model is in part due to reduced production of 2-
arachidonylglycerol (2-AG) and increased catabolic 
hydroxylation of N-arachidonoylethanolamine (AEA) .43 
CBD has shown to increase both AEA and 2-AG 
availability improving one of the biological mechanisms 
of FXS.45 
 There are other mechanisms that have been involved 
in the potential benefits of CBD in FXS. Altered synaptic 
function and structure has been established as one of the 
major mechanisms of FXS.46 It has been proposed that 
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CBD may increase synaptic plasticity in FXS which may 
be associated with an improvement in learning and 
cognition domains.47,48,49 Additionally, alterations in the 
GABAergic system have also been implicated in FXS 
pathogenesis and pharmacological treatment with 
agonists of the GABA receptor have been shown to 
improve several behavioral deficits in the FXS mouse 
model50. CBD may also improve the GABAergic 
dysfunction since it acts as a positive allosteric 
modulator of GABAA receptors.
51 
 Finally, CBD exerts its anxiolytic effects by its 
interaction with the serotonin system. Studies have 
identified serotonin-1A receptor (5-HT1A) as one of the 
targets through which CBD aids in the reduction of 
social anxiety experienced by patients with FXS.52,53 
 Side effects of CBD appear to be minimal and it is 
generally well tolerated. In 2011, Bergamaschi et al. 
performed a systematic review on the safety and side 
effects of CBD and found that chronic use and high 
doses of CBD were reportedly well tolerated in 
humans.54 Some patients may experience transitory, 
dose-dependent mild to moderate effects including 
somnolence, decreased appetite and gastrointestinal 
disturbances.55 Studies in patients with treatment-
resistant epilepsy being treated with CBD reported that 
the most common adverse effects were somnolence, 
diarrhea and decreased appetite. Significant elevation of 
liver enzymes was reported as a serious adverse effect, 
especially among patients treated with high dose CBD 
and concomitant valproic acid.56,57 In general, CBD has 
shown a favorable safety profile and tolerability which 
has allowed for several clinical trials to be approved. 
 CBD is a promising targeted treatment for FXS since 
it has effects in most of the pathways associated with 
FXS pathogenesis. A case series was published in 201944 
in which a child and two adults with FXS were treated 
with oral botanical CBD+ solutions. In this case series 
there were parent-reported improvements in domains 
such as social avoidance, anxiety, sleep pattern, appetite, 
motor coordination, language and sensory processing 
while taking the CBD. Two of the patients re-
experienced some of the FXS symptoms upon cessation 
of CBD and improved after the reintroduction of the 
treatment. A phase 2 open label trial of a CBD 
transdermal gel in 20 children with FXS was carried out 
in Australia. The results showed a significant reduction 
in anxiety and improvement in behavioral measures such 
as social avoidance and irritability.58 A phase 3 
randomized, double-blinded, placebo-controlled, multi-
center study assessing the efficacy and safety of a 
pharmaceutically manufactured CBD, formulated as a 
transdermal gel, for the treatment of patients with FXS 
is currently taking place in the United States and 
Australia (NCT03614663). The results are yet to be 
reported. CBD seems to be a promising intervention for 
individuals with FXS.  
 
Ganaxolone 
 Ganaxolone is a 3β-methylated synthetic analog of 
allopregnanolone and is classified as a neurosteroid. 
Ganaxolone is a positive allosteric modulator of GABAA 
receptor in the CNS and it does not have inadvertent 
hormonal effects. Ganaxolone has been studied for 
treatment of epilepsy, anxiety, and depression. 
Preclinical studies found that treatment with ganaxolone 
can reduce repetitive and perseverative behaviors in the 
Fmr1-KO mice in a dose-dependent association in 
addition to modulating sensory response.59 A randomized 
controlled trial in 59 youth aged 6-17 years old with FXS 
found promising benefits of ganaxolone in hyperactivity, 
attention, and anxiety domains but only in participants 
who had a high level of anxiety and lower cognitive 
function (i.e., full-scale IQ ≤ 45). Although more adverse 
events were reported in the ganaxolone group (i.e., 
fatigue, drowsiness), no serious adverse events were 
observed, and most events were recovered60. Further 
studies should specifically include younger children with 
low cognitive function and a high level of anxiety. 
 
Gaboxadol (OV101) 
 Gaboxadol augments a δ-subunit-containing extrasy 
naptic GABAA receptor. A preclinical study observed 
that hyperactivity, anxiety, aggression, and repetitive 
behaviors in the animal model of FXS can be returned to 
typical behaviors after treatment with intraperitoneal 
gaboxadol61. There is an ongoing randomized open label 
study in males aged 13 to 22 years old which aims to 
assess safety and improvement in the ABC-C after 12 
weeks on gaboxadol (see table 1). 
 
Arbaclofen 
 As previously mentioned, GABAergic system 
dysfunction has been implicated in FXS pathogenesis and 
therefore GABA agonists have been studied as potential 
targeted treatments. The administration of GABAA 
agonist, alphaxalone, in Fmr1-KO mice resulted in a 
clear anxiolytic effect and improvement in elevated plus 
maze performance62. Furthermore, studies in Fmr1-KO 
mice and GABAB agonist, baclofen, showed protection 
from audiogenic seizures.63 In other studies using 
baclofen in Fmr1-KO mice, improvement and correction 
of abnormalities involved in FXS pathophysiology were 
observed such as correction of excessive basal protein 
synthesis, which affects functional plasticity, and 
abnormal spine density.64,65 These promising results lead 
to clinical trials in patients with FXS. 
 Arbaclofen is the R-enantiomer of baclofen, a 
GABAB agonist. Two phase 3 placebo-controlled trials 
with arbaclofen involving patients with FXS showed that 
arbaclofen did not improve social avoidance in FXS. The 
pediatric study which recruited subjects age 5-11, 
showed that the highest dose group had a beneficial effect 
over placebo on the ABC-C, FXS-specific (ABC-CFX) 
irritability sub scale and Parenting Stress Index, but the 
primary outcome measure of the study was not met66. 
 
Selective mGluR5 antagonist: Mavoglurant 
 FMRP loss in FXS leads to up regulation of mGluR 
and aberrant glutamate signaling.67 In Fmr1-KO mice, up 
regulation of the group I mGluR was associated with 
enhancement of synaptic LTD which is a mechanism 
involved in learning and memory.68 This provided the 
basis for the development of specific drugs targeting and 
antagonizing these receptors. Since mGluR5 is expressed 
in areas of the brain involved in emotion and motivation, 
it was proposed as a therapeutic target in FXS.69 
Mavoglurant (AFQ056) was developed as a selective 
non-competitive mGluR5 antagonists capable of 
27 
 
 
Journal of Biomedicine and Translational Research, 6 (1) 2020, 23-33 
blocking the excessive downstream signaling through 
mGluR5,70 which in FXS occurs due to loss of the 
negative regulatory function of FMRP.  
 In preclinical studies mavoglurant demonstrated 
positive neuronal and behavioral effects.71,72 Despite 
these promising results, mavoglurant failed to show 
beneficial behavioral effects in two 12-week 
randomized, placebo-controlled, double-blind, phase 2 
studies in adult and adolescent patients with FXS73. The 
primary outcome in these studies was improvement on 
behavioral symptoms measured by the ABC-CFX after 12 
weeks of treatment. None of the two studies showed 
efficacy in reducing the ABC-CFX total score after 12 
weeks of treatment with any of the doses of mavoglurant 
studied vs placebo. In 2018 Hagerman et al. reported the 
results of two open-label extension trials. Long term 
safety was the primary endpoint and efficacy the 
secondary one. Although mavoglurant was well 
tolerated and there were no safety concerns, the trial was 
discontinued earlier than planned due to lack of proven 
efficacy in the core-controlled studies.74 It has been 
proposed that mavoglurant may be effective in specific 
experimental settings such as younger age groups and 
longer trial periods. Currently, there is a phase 2 clinical 
trial recruiting patients between 32 months to 6 years to 
evaluate if mavoglurant (AFQ056) can have a positive 
impact in language measured by the Weighted Child 
Intentional Communication Score (see table 1) 
(NCT02920892). It is estimated to be completed by July 
2020. There is a need for future clinical trials to 
demonstrate if there are clinical behavioral and cognitive 
benefits of mavoglurant in patients with FXS. 
 
Lovastatin 
 Lovastatin is a 3-hydroxy-3-methylglutaryl-
coenzyme A reductase inhibitor which is indicated for 
treatment of hypercholesterolemia. Ras-ERK1/2 
signaling, mGluR-LTD, and excess proteins are 
downregulated by lovastatin which results in 
epileptogenic inhibition at the hippocampal area and 
blocks cortical hyperexcitability in the Fmr1-KO mouse 
model.75,76 In patients with FXS, an open-label phase I 
trial was conducted to assess safety and efficacy of 
lovastatin in 16 individuals with FXS aged between 10-
40 years old.77  Subjects were initially treated with 20 
mg of lovastatin for the first 4 weeks and titrated up to 
40 mg for the next 8 weeks. Participants showed 
behavioral and adaptive skills improvement over time. 
Short-term safety of lovastatin was also reported by the 
trial. Ongoing randomized controlled trials to investigate 
efficacy of lovastatin in combination with a language 
intervention and other medications in the pediatric 
population await results (see table 1).     
 
Acamprosate  
 Acamprosate is a medication for the maintenance of 
abstinence from alcohol dependence. It is a gamma-
aminobutyric acid agonist while it modulates NMDA 
receptor and decreases neuronal hyperexcitability in 
preclinical studies.78,79 Acamprosate might normalize 
the plasma amyloid-β precursor protein which is 
elevated in youth with FXS and ASD80. A prospective 
open-label study in 12 youth with FXS age 6-17 years 
old found that 75% of participants had improvement in 
hyperactivity, irritability, social interaction, and 
communication after taking acamprosate for 10 weeks81. 
In this study, acamprosate was started at 333 mg a day 
for the first week and titrated up to an average of 
1054±422 mg a day in the subsequent 5 weeks. 
Improvement in the BDNF level was also observed but a 
correlation between the BDNF level and behavioral 
improvement was not established. Currently, an active 
phase 2/phase 3 randomized-controlled trial aims to 
analyze the effect of treatment with acamprosate in a 10-
weeks period in the problematic behaviors seen in 
patients with FXS (see table 1). Acamprosate has also 
been proposed as a beneficial treatment for patients with 
FXS syndrome diagnosed with alcohol dependency 
because it is helpful for both problems.82    
 
Riluzole 
 Riluzole is a glutamate-modulating agent known for 
its use in amyotrophic lateral sclerosis. It acts by 
inhibiting glutamate release and enhancing its 
presynaptic reuptake.83 Since as stated earlier, 
glutamatergic dysregulation is part of the pathogenesis of 
FXS, riluzole was proposed as a potential targeted 
treatment.  In the only published clinical trial studying 
riluzole in patients with FXS, 6 adults received open-
label treatment with riluzole for six weeks. Investigators 
did not find significant clinical improvement and the 
primary outcome, which was improvement in repetitive 
and compulsive behaviors, was not met84. 
 
Trofinetide (NNZ-2566) 
 Trofinetide (NNZ-2566) is a synthetic analogue of 
glypromate (glycine-proline glutamate; GPE). 
Glypromate is a derivate of insulin-like growth factor-1 
(IGF-1) with neuroprotective properties.85 There are 
several neuroprotective mechanisms proposed for GPE 
including inhibition of caspase-3-dependent apoptosis by 
preventing amyloid beta-peptide mediated activation.86 
Studies of GPE given as intravenous injection in 
hypoxic-ischemic adult rat models showed it was able to 
reduce caspase-3-dependent and caspase-independent 
apoptosis in the hippocampus, inhibit microglial 
proliferation and prevent injury-induced loss of 
astrocytes87. Due to its neuroprotective effects it was 
proposed as a treatment for neurodevelopmental 
disorders such as Rett syndrome. In clinical trials, it has 
been proven to have potential for treating core symptoms 
in patients with Rett syndrome, such as anxiety-like 
behaviors, disruptive behavior and mood dysregulation.88 
 Deacon et al. studied the effects of trofinetide in 
Fmr1-KO mice and found it normalized dendritic spine 
density and overactive ERK and protein kinase B (Akt) 
signaling, suggesting a unique disease modifying 
mechanism for trofinetide in FXS.89 In their study, 
normalization of activation of the Ras-MAPK ad PI3K-
Akt-mTOR activation was accompanied by improvement 
in behavioral function such as restoration of social 
recognition. Furthermore, trofinetide was shown to be 
safe in a phase 2 clinical trial (NCT01894958), but there 
are to date no published results on further trials studying 
it in patients with FXS. 
 
 
  
Medication 
 
Mechanism Code/status Phase Age/sex Primary outcome 
Metformin Normalizing ERK signaling, EIF4E 
phosphorylation, mTOR and PI3K activities in 
CNS, and lowering expression of MMP9 to 
normal 
NCT03722290/recruiting 2 10-40 y Safety 
Changes in the total score of the fragile X-normed aberrant behavior 
checklist-community 
 NCT04141163/recruiting 1, 2 18-50 
y/male 
Safety and tolerability  
 NCT03862950/recruiting  2 6-25 y Changes in the expressive language sampling mean number of different 
words score 
 NCT03479476/recruiting 
 
2, 3 
 
6-25 y Changes in the expressive language sampling mean number of different 
words score 
 
Low dose 
sertraline 
Stimulation of BDNF NCT01474746/published (Reference 32) 2 24-68 m  Changes in Mullen scales of early learning- expressive language raw 
Score and clinical global impression-improvement 
Cannabidiol Regulation of abnormal endocannabinoid 
signaling 
NCT03614663/active, not recruiting 
 
2,3 
 
3-17 y Improvement in aberrant behavior checklist-community fragile X factor 
structure  
 NCT03802799/recruiting 
 
2,3 
 
3-18 y Safety and tolerability 
Ganaxolone Neurosteroid 
Modulate GABAA 
NCT01725152/published (Reference 60) 
 
2 
 
6-17 y Clinician's global impression-improvement  
Gaboxadol 
(OV101) 
 NCT03697161/active, not recruiting  2 
 
13-22 y,  
males 
Safety  
 NCT03109756/completed 1 13-17 y Pharmacokinetic   
Mavoglurant mGluR5 receptor antagonists. Blocks excess 
mGluRI signaling. 
NCT02920892/recruiting 2 
 
32 months – 
6 years 
Greater improvement in language-weighted child intentional 
communication score 
 
Lovastatin RAS signaling inhibitor NCT02680379/completed 
 
2 8-45 y Change from baseline aberrant behavior checklist-community  
 
 NCT02642653a/completed 4 
 
10-17 y Expressive language sample composite score in the home 
Acamprosate Activate GABAA and GABAB receptor NCT01300923/published
 (Reference 81) 2 5-17 y Clinical global impression- severity scale  
 NCT01911455/active, not recruiting 2, 3 5-23 y Aberrant Behavior Checklist-Social Withdrawal subscale  
 NCT02998151b/enrolling 
 
2 
 
15-55 y Change in EEG aspects of auditory processing and clinical global 
impressions improvement 
 
Trofinetide 
(NNZ-2566) 
Block excess mGluRI signalling by normalizing 
activation of the Ras-MAPK and PI3K-Akt-
mToR pathway 
 
NCT01894958/completed 2 12-45 y/ 
males 
Safety 
Donepezil Enhances acetylcholine function in the brain NCT01120626/published (Reference 91) 
 
2 
 
12-29 y Contingency naming test performance score 
aCombining lovastatin and a parent-implemented language intervention in a multimodal treatment for FXS 
bEvaluating the neurophysiologic and clinical effects of single-dose acamprosate, lovastatin, minocycline, and placebo in FXS 
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Donepezil 
 Donepezil is a cholinesterase inhibitor which 
has been used for the treatment dementia. A study found 
lower choline/creatinine ratio in the right dorsolateral 
prefrontal cortex of 9 males with FXS compared with 
typical developing males.90 Eight participants aged 14-
44 years old who took donepezil 5 mg for 3 weeks 
followed by 10 mg for 3 weeks showed improvement in 
cognitive and behavioral status.90 However, a 
subsequent 12 week-randomized controlled trial of 
donepezil in 42 individuals with FXS did not prove the 
effects91. Perhaps improvement in cognitive-behavioral 
function needs a combination of behavioral 
interventions with medication treatment. Nevertheless, 
functional brain magnetic resonance imaging of 
participants in the donepezil group showed that the left 
superior frontal gyrus was less activated to stimuli tasks 
compared to the placebo group. This finding might 
reflect an effect of donepezil in restoring the abnormal 
neuroimaging phenotype in FXS. Future studies to 
assess the change in brain functioning may early capture 
the efficacy of treatment with donepezil.      
 
Challenges in the search for a targeted treatment in 
FXS 
 Thanks to the advancement and the identification of 
multiple pathways involved in FXS pathogenesis, there 
are numerous studies targeting the altered pathways in 
the seek for therapeutic interventions that are specific for 
FXS. Several animal models have proven promising 
results in behavioral and cognitive endpoints and have 
led to clinical trials in humans with varying 
results92.What are the main challenges for translation 
into beneficial therapy for humans? Zeidler and 
colleagues reviewed the limitations in the search for a 
targeted treatment for FXS in 2019.93 The main 
limitations identified where the extrapolation of results 
from animal models to humans, the outcome measures 
used in different studies, the trial design and the need to 
target more than one pathway.  
 In 2017 Budimirovic and colleagues evaluated the 
available outcome measures for trials involving FXS or 
other neurodevelopment disorders. They concluded that 
most of the outcome measures were of moderate quality 
level with limited information on reliability, validity, 
and sensitivity to treatment94. There is ongoing research 
for the development of more sensitive and reproducible 
measurement tools such as white matter changes,95 
auditory evoked potentials measures96, eye-tracking,97 
among others.   
 Additionally, since there are multiple pathways 
involved in FXS pathogenesis, a combination of 
medications or medications targeting multiple pathways 
could be more beneficial24. Trials involving medication 
and non-pharmacological interventions such as Parent 
Implemented Language Intervention (PILI) could also 
be more sustainable and beneficial. Clinical trials 
focusing on multimodal interventions are promising and 
despite the limitations in the search for targeted 
treatment, there has been a significant advancement in 
implementing clinical trials in FXS. 
 
 
 
CONCLUSION  
 Although there are currently no disease-modifying 
treatments for FXS with regulatory approval, there are 
several potential medications targeting different 
pathways involved in FXS pathophysiology. The current 
approach when treating a patient with FXS focuses 
mostly on symptomatic off-label treatment. Thanks to the 
increasing understanding of FXS pathogenesis, clinical 
trials have been performed and several agents show 
promising results.  
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